Novo Nordisk A/S (NOVO B)

Basic

  • Market Cap

    DKK 3,116.52B

  • EV

    DKK 3,095.46B

  • Shares Out

    4,460.45M

  • Revenue

    DKK 214.49B

  • Employees

    61,412

Margins

  • Gross

    84.14%

  • EBITDA

    46.67%

  • Operating

    43.69%

  • Pre-Tax

    43.53%

  • Net

    35.11%

  • FCF

    39.67%

Returns (5Yr Avg)

  • ROA

    24.8%

  • ROE

    72.03%

  • ROCE

    77.29%

  • ROIC

    36.73%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • EV/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    DKK 680.04

  • P/E

  • EV/Sales

  • EV/EBITDA

  • EV/FCF

Per Share

  • Rev

    DKK 47.73

  • Earnings (Dil)

    DKK 16.71

  • FCF

    DKK 18.88

  • Book Value

    DKK 20.77

Growth (CAGR)

  • Rev 3Yr

    19.02%

  • Rev 5Yr

    14.27%

  • Rev 10Yr

    9.98%

  • Dil EPS 3Yr

    23.63%

  • Dil EPS 5Yr

    16.25%

  • Dil EPS 10Yr

    13.79%

  • Rev Fwd 2Yr

    25.22%

  • EBITDA Fwd 2Yr

    27.81%

  • EPS Fwd 2Yr

    34.81%

  • EPS LT Growth Est

    20.91%

Dividends

  • Yield

  • Payout

    42.21%

  • DPS

    DKK 7.08

  • DPS Growth 3Yr

    18.06%

  • DPS Growth 5Yr

    12.51%

  • DPS Growth 10Yr

    14.67%

  • DPS Growth Fwd 2Yr

    29.11%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM

Total Revenues

111,831.0

122,021.0

126,946.0

140,800.0

176,954.0

214,490.0

Total Revenues % Chg.

0.1%

9.1%

4.0%

10.9%

25.7%

28.3%

Cost of Goods Sold, Total

17,617.0

20,088.0

20,932.0

23,658.0

28,448.0

34,013.0

Gross Profit

94,214.0

101,933.0

106,014.0

117,142.0

148,506.0

180,477.0

Selling General & Admin Expenses, Total

33,313.0

35,830.0

36,886.0

41,058.0

50,684.0

58,063.0

R&D Expenses

14,805.0

14,220.0

15,462.0

17,199.0

23,287.0

29,308.0

Other Operating Expenses

-1,152.0

-600.0

-460.0

-456.0

-1,085.0

-600.0

Other Operating Expenses, Total

46,966.0

49,450.0

51,888.0

57,801.0

72,886.0

86,771.0

Operating Income

47,248.0

52,483.0

54,126.0

59,341.0

75,620.0

93,706.0

Interest Expense, Total

-85.0

-220.0

-390.0

-289.0

-378.0

-378.0

Interest And Investment Income

51.0

65.0

337.0

231.0

239.0

239.0

Net Interest Expenses

-34.0

-155.0

-53.0

-58.0

-139.0

-139.0

Income (Loss) On Equity Invest.

12.0

-137.0

149.0

-24.0

-189.0

-189.0

Currency Exchange Gains (Loss)

298.0

-3,212.0

-747.0

344.0

-4,651.0

433.0

Other Non Operating Income (Expenses)

-72.0

-281.0

-150.0

-122.0

-181.0

957.0

EBT, Excl. Unusual Items

47,452.0

48,698.0

53,325.0

59,481.0

70,460.0

94,768.0

Merger & Related Restructuring Charges

-124.0

-51.0

-51.0

Gain (Loss) On Sale Of Investments

163.0

-145.0

-195.0

296.0

-587.0

-587.0

Gain (Loss) On Sale Of Assets

Asset Writedown

-573.0

-760.0

-760.0

Other Unusual Items

EBT, Incl. Unusual Items

47,615.0

48,553.0

53,130.0

59,080.0

69,062.0

93,370.0

Income Tax Expense

8,987.0

9,602.0

10,992.0

11,323.0

13,537.0

18,058.0

Earnings From Continuing Operations

38,628.0

38,951.0

42,138.0

47,757.0

55,525.0

75,312.0

Net Income

38,628.0

38,951.0

42,138.0

47,757.0

55,525.0

75,312.0

Net Income to Common Incl Extra Items

38,628.0

38,951.0

42,138.0

47,757.0

55,525.0

75,312.0

Net Income to Common Excl. Extra Items

38,628.0

38,951.0

42,138.0

47,757.0

55,525.0

75,312.0

Total Shares Outstanding

4,788.0

4,704.0

4,625.0

4,557.8

4,500.7

4,476.9

Weighted Avg. Shares Outstanding

4,839.2

4,748.6

4,667.8

4,593.2

4,530.6

4,493.5

Weighted Avg. Shares Outstanding Dil

4,848.8

4,757.4

4,680.0

4,606.2

4,544.6

4,506.8

EPS

8.0

8.2

9.0

10.4

12.3

16.8

EPS Diluted

8.0

8.2

9.0

10.4

12.2

16.7

EBITDA

51,173.0

56,310.0

58,565.0

63,553.0

80,926.0

100,106.0